ENHANCEDUNLOCK YOUR POTENTIAL
← Back to ENHANCED
RESEARCH PROTOCOLS / EXPOSURE ATLAS

What was actually
tested?

A large-scale, source-linked index of published research exposure. See the doses, concentrations, routes, frequencies and timeframes used in studies — without turning study design into a recommendation.

STUDIED EXPOSURE, NOT DOSING ADVICEHUMAN + PRECLINICALROUTE KEPT ATTACHEDNO ANIMAL→HUMAN CONVERSIONS
RESEARCH ENTITIES53 indexed
SOURCE-LINKED EXPOSURE MAPS28 live
HUMAN / CLINICAL MAPS23 source-linked
RANKINGS / RECOMMENDATIONS0
STUDIED EXPOSURE ATLAS

Numbers with their context still attached.

A dose without route, model, schedule and source is easy to misuse. ENHANCED keeps those pieces together. Human trial exposure is labelled human. Mouse exposure stays mouse. Topical concentrations stay topical.

HUMAN STUDY MAPS23
PRECLINICAL / TRANSLATIONAL / IN-VITRO5
CATALOGUE + BROADER INDEX53 entities
PERSONAL DOSE OUTPUTNONE
RETATRUTIDE1 · 4 · 8 · 12 mgCAGRILINTIDE0.3 → 4.5 mgSS310.01 → 0.25 mg/kg/hARA-2904 mgBPC-157 / RAT10 µg → 10 pg/kgSEMAGLUTIDE2 · 8 · 16 mg
SOURCE-LINKED / FEATURED MAPS

Read the exposure.
Keep the study attached.

Every map separates what researchers tested from what anyone should do. Exact route and evidence type stay visible beside the number.

HUMAN / RANDOMIZED PHASE 22023
RetatrutideNew England Journal of Medicine

Retatrutide

GLP-1, GIP and glucagon receptor research

STUDIED EXPOSURE1 mg · 4 mg · 8 mg · 12 mg
OPEN EXPOSURE MAP→
HUMAN / DOSE-FINDING PHASE 22021
Cagrilintide ENHANCED Research Index vialThe Lancet

Cagrilintide

Published research exposure and study-design context

STUDIED EXPOSURE0.3 mg · 0.6 mg · 1.2 mg · 2.4 mg
OPEN EXPOSURE MAP→
HUMAN / RANDOMIZED PHASE I–II2018
SS31 / ElamipretideNeurology

SS31 / Elamipretide

Mitochondrial-targeting peptide research

STUDIED EXPOSURE0.01 mg/kg/h · 0.1 mg/kg/h · 0.25 mg/kg/h
OPEN EXPOSURE MAP→
HUMAN / PHASE 22015
ARA-290 / CibinetideMolecular Medicine

ARA-290 / Cibinetide

Tissue-protective and inflammatory-signalling research

STUDIED EXPOSURE4 mg
OPEN EXPOSURE MAP→
PRECLINICAL / RAT + IN VITRO2003
BPC-157Journal of Orthopaedic Research

BPC-157

Tissue-repair and recovery signalling research

STUDIED EXPOSURE10 µg/kg · 10 ng/kg · 10 pg/kg
OPEN EXPOSURE MAP→
HUMAN / RANDOMIZED PHASE 22025
Semaglutide ENHANCED Research Index vialDiabetes Care

Semaglutide

Published research exposure and study-design context

STUDIED EXPOSURE2 mg · 8 mg · 16 mg
OPEN EXPOSURE MAP→
A–Z / LARGE-SCALE INDEX

53 research entities.

Current ENHANCED catalogue profiles sit beside a broader educational research index. Broader-index entries are informational references and are not part of the ENHANCED catalogue.

5-Amino-1MQ
Metabolic Research

5-Amino-1MQ

50mg
ENHANCED CATALOGUESOURCE + EXPOSURE MAPPED

Nicotinamide N-methyltransferase (NNMT) research

EVIDENCE CONTEXTProfile context
STUDIED EXPOSURE20 mg/kg/injection · 10–150 mg/kg/daySubcutaneous · three injections/day
OPEN EXPOSURE MAP →RESEARCH PROFILE ↗
Afamelanotide ENHANCED Research Index vial
Endocrine Research

Afamelanotide

Broader research index
BROADER RESEARCH INDEXEVIDENCE INDEX

Melanocortin receptor agonist research

EVIDENCE CONTEXTEstablished human clinical literature
OPEN EVIDENCE PROFILE →
AOD-9604 ENHANCED Research Index vial
Metabolic Research

AOD-9604

Broader research index
BROADER RESEARCH INDEXEVIDENCE INDEX

Growth-hormone fragment research

EVIDENCE CONTEXTHuman development + preclinical
OPEN EVIDENCE PROFILE →
ARA-290
Performance & Recovery

ARA-290

10mg
ENHANCED CATALOGUESOURCE + EXPOSURE MAPPED

Tissue-protective and inflammatory-signalling research

EVIDENCE CONTEXTProfile context
STUDIED EXPOSURE4 mgSubcutaneous · self-administered
OPEN EXPOSURE MAP →RESEARCH PROFILE ↗
BPC-157
Performance & Recovery

BPC-157

10mg
ENHANCED CATALOGUESOURCE + EXPOSURE MAPPED

Tissue-repair and recovery signalling research

EVIDENCE CONTEXTProfile context
STUDIED EXPOSURE10 µg/kg · 10 ng/kg · 10 pg/kgIntraperitoneal · once daily in animal model
OPEN EXPOSURE MAP →RESEARCH PROFILE ↗
Cagrilintide ENHANCED Research Index vial
Metabolic Research

Cagrilintide

Broader research index
BROADER RESEARCH INDEXSOURCE + EXPOSURE MAPPED

Long-acting amylin-analogue research

EVIDENCE CONTEXTHuman phase 2–3
STUDIED EXPOSURE0.3 mg · 0.6 mg · 1.2 mgSubcutaneous · once weekly
OPEN EXPOSURE MAP →
Cagrilintide + Semaglutide ENHANCED Research Index vial
Metabolic Research

Cagrilintide + Semaglutide

Broader research index
BROADER RESEARCH INDEXSOURCE + EXPOSURE MAPPED

Combined amylin + GLP-1 research

EVIDENCE CONTEXTHuman phase 3
STUDIED EXPOSURE2.4 mg cagrilintide + 2.4 mg semaglutideSubcutaneous · once weekly
OPEN EXPOSURE MAP →
CJC 1295 + DAC
Performance & Recovery

CJC 1295 + DAC

10mg
ENHANCED CATALOGUESOURCE + EXPOSURE MAPPED

Longer-acting GHRH analogue research

EVIDENCE CONTEXTProfile context
STUDIED EXPOSURE30 µg/kg · 60 µg/kg · 125 µg/kgSubcutaneous
OPEN EXPOSURE MAP →RESEARCH PROFILE ↗
CJC 1295 NO DAC + Ipamorelin
Performance & Recovery

CJC 1295 NO DAC + Ipamorelin

10mg
ENHANCED CATALOGUEEVIDENCE INDEX

Combined GHRH and secretagogue research

EVIDENCE CONTEXTProfile context
RESEARCH PROFILE ↗
DSIP
Cognitive & Neuro Support

DSIP

10mg
ENHANCED CATALOGUESOURCE + EXPOSURE MAPPED

Delta sleep-inducing peptide research

EVIDENCE CONTEXTProfile context
STUDIED EXPOSURE25 nmol/kgIntravenous
OPEN EXPOSURE MAP →RESEARCH PROFILE ↗
Epithalon
Longevity Research

Epithalon

50mg
ENHANCED CATALOGUEEVIDENCE INDEX

Aging-biology and cellular-regulation research

EVIDENCE CONTEXTProfile context
RESEARCH PROFILE ↗
Follistatin-344 ENHANCED Research Index vial
Growth Signalling

Follistatin-344

Broader research index
BROADER RESEARCH INDEXEVIDENCE INDEX

Activin / myostatin pathway research

EVIDENCE CONTEXTPreclinical / translational
OPEN EVIDENCE PROFILE →
FOXO4-DRI ENHANCED Research Index vial
Longevity & Cellular

FOXO4-DRI

Broader research index
BROADER RESEARCH INDEXEVIDENCE INDEX

Senescence-pathway research

EVIDENCE CONTEXTPreclinical
OPEN EVIDENCE PROFILE →
GHK-Cu
Longevity Research

GHK-Cu

100mg · 50mg
ENHANCED CATALOGUESOURCE + EXPOSURE MAPPED

Copper-peptide and tissue biology research

EVIDENCE CONTEXTProfile context
STUDIED EXPOSURE0.01 nM · 1 nM · 100 nMIn vitro concentration; topical human use summarized separately
OPEN EXPOSURE MAP →RESEARCH PROFILE ↗
GHRP-2 ENHANCED Research Index vial
Growth Signalling

GHRP-2

Broader research index
BROADER RESEARCH INDEXEVIDENCE INDEX

Ghrelin-receptor / GH-secretagogue research

EVIDENCE CONTEXTHuman pharmacology
OPEN EVIDENCE PROFILE →
GHRP-6 ENHANCED Research Index vial
Growth Signalling

GHRP-6

Broader research index
BROADER RESEARCH INDEXSOURCE + EXPOSURE MAPPED

Ghrelin-receptor / GH-secretagogue research

EVIDENCE CONTEXTHuman pharmacokinetics
STUDIED EXPOSURE100 µg/kg · 200 µg/kg · 400 µg/kgSingle intravenous bolus
OPEN EXPOSURE MAP →
GLOW
Performance & Recovery

GLOW

70mg
ENHANCED CATALOGUEEVIDENCE INDEX

Multi-compound recovery research blend

EVIDENCE CONTEXTProfile context
RESEARCH PROFILE ↗
Glutathione
Longevity Research

Glutathione

1500mg
ENHANCED CATALOGUESOURCE + EXPOSURE MAPPED

Antioxidant and redox research

EVIDENCE CONTEXTProfile context
STUDIED EXPOSURE250 mg/day · 1,000 mg/dayOral
OPEN EXPOSURE MAP →RESEARCH PROFILE ↗
HCG
Endocrine Research

HCG

10,000 IU
ENHANCED CATALOGUEEVIDENCE INDEX

LH-receptor and recompoundive-endocrine research

EVIDENCE CONTEXTProfile context
RESEARCH PROFILE ↗
Hexarelin ENHANCED Research Index vial
Growth Signalling

Hexarelin

Broader research index
BROADER RESEARCH INDEXSOURCE + EXPOSURE MAPPED

GH-secretagogue research

EVIDENCE CONTEXTHuman pharmacology
STUDIED EXPOSURE0–1.0 µg/kgIntravenous
OPEN EXPOSURE MAP →
Humanin ENHANCED Research Index vial
Longevity & Cellular

Humanin

Broader research index
BROADER RESEARCH INDEXEVIDENCE INDEX

Mitochondrial-derived peptide research

EVIDENCE CONTEXTPreclinical / translational
OPEN EVIDENCE PROFILE →
IGF-1 LR3
Endocrine Research

IGF-1 LR3

1mg
ENHANCED CATALOGUEEVIDENCE INDEX

IGF-1 receptor and growth-factor research

EVIDENCE CONTEXTProfile context
RESEARCH PROFILE ↗
Ipamorelin
Performance & Recovery

Ipamorelin

10mg
ENHANCED CATALOGUESOURCE + EXPOSURE MAPPED

Growth-hormone secretagogue research

EVIDENCE CONTEXTProfile context
STUDIED EXPOSURE4.21 nmol/kg · 14.02 nmol/kg · 42.13 nmol/kgIntravenous infusion over 15 minutes
OPEN EXPOSURE MAP →RESEARCH PROFILE ↗
Kisspeptin
Endocrine Research

Kisspeptin

10mg
ENHANCED CATALOGUESOURCE + EXPOSURE MAPPED

KISS1R and recompoundive-axis research

EVIDENCE CONTEXTProfile context
STUDIED EXPOSURE0.3 nmol/kg · 1.0 nmol/kg · 3.0 nmol/kgIntravenous bolus; additional route experiments were also performed
OPEN EXPOSURE MAP →RESEARCH PROFILE ↗
KLOW
Endocrine Research

KLOW

80mg
ENHANCED CATALOGUEEVIDENCE INDEX

Research-blend presentation

EVIDENCE CONTEXTProfile context
RESEARCH PROFILE ↗
KPV ENHANCED Research Index vial
Recovery & Tissue

KPV

Broader research index
BROADER RESEARCH INDEXEVIDENCE INDEX

Alpha-MSH fragment / inflammatory-pathway research

EVIDENCE CONTEXTPreclinical
OPEN EVIDENCE PROFILE →
Liraglutide ENHANCED Research Index vial
Metabolic Research

Liraglutide

Broader research index
BROADER RESEARCH INDEXSOURCE + EXPOSURE MAPPED

GLP-1 analogue research

EVIDENCE CONTEXTExtensive human clinical literature
STUDIED EXPOSURE3.0 mgSubcutaneous · once daily
OPEN EXPOSURE MAP →
LL-37
Performance & Recovery

LL-37

5mg
ENHANCED CATALOGUESOURCE + EXPOSURE MAPPED

Cathelicidin and innate-immunity research

EVIDENCE CONTEXTProfile context
STUDIED EXPOSURE0.5 mg/mL · 1.6 mg/mL · 3.2 mg/mLTopical wound application
OPEN EXPOSURE MAP →RESEARCH PROFILE ↗
Mazdutide ENHANCED Research Index vial
Metabolic Research

Mazdutide

Broader research index
BROADER RESEARCH INDEXSOURCE + EXPOSURE MAPPED

GLP-1 + glucagon dual-agonist research

EVIDENCE CONTEXTHuman phase 2–3
STUDIED EXPOSURE3→6 mg · 10 mg · 16 mgSubcutaneous · once weekly
OPEN EXPOSURE MAP →
MOTS-C
Metabolic Research

MOTS-C

40mg
ENHANCED CATALOGUESOURCE + EXPOSURE MAPPED

Mitochondrial-derived peptide research

EVIDENCE CONTEXTProfile context
STUDIED EXPOSURE5 mg/kg/day · 15 mg/kg/dayIntraperitoneal in mouse intervention experiments
OPEN EXPOSURE MAP →RESEARCH PROFILE ↗
NAD+
Longevity Research

NAD+

1000mg
ENHANCED CATALOGUESOURCE + EXPOSURE MAPPED

Cellular redox and energy-metabolism research

EVIDENCE CONTEXTProfile context
STUDIED EXPOSURE750 mg total · 3 µmol/minIntravenous infusion
OPEN EXPOSURE MAP →RESEARCH PROFILE ↗
PE-22-28 ENHANCED Research Index vial
Cognitive & Neuro

PE-22-28

Broader research index
BROADER RESEARCH INDEXEVIDENCE INDEX

Neurotrophic / antidepressant-model research

EVIDENCE CONTEXTPreclinical
OPEN EVIDENCE PROFILE →
PEG-MGF ENHANCED Research Index vial
Growth Signalling

PEG-MGF

Broader research index
BROADER RESEARCH INDEXEVIDENCE INDEX

Mechano-growth-factor analogue research

EVIDENCE CONTEXTPreclinical
OPEN EVIDENCE PROFILE →
Pemvidutide ENHANCED Research Index vial
Metabolic Research

Pemvidutide

Broader research index
BROADER RESEARCH INDEXSOURCE + EXPOSURE MAPPED

GLP-1 + glucagon dual-agonist research

EVIDENCE CONTEXTHuman phase 2
STUDIED EXPOSURE1.2 mg · 1.8 mg · 2.4 mgSubcutaneous · once weekly
OPEN EXPOSURE MAP →
Pinealon
Longevity Research

Pinealon

10mg
ENHANCED CATALOGUEEVIDENCE INDEX

Neurobiology and cognitive research

EVIDENCE CONTEXTProfile context
RESEARCH PROFILE ↗
PNC-27 ENHANCED Research Index vial
Oncology Research

PNC-27

Broader research index
BROADER RESEARCH INDEXEVIDENCE INDEX

p53-derived membrane-disruptive peptide research

EVIDENCE CONTEXTPreclinical
OPEN EVIDENCE PROFILE →
Pramlintide ENHANCED Research Index vial
Metabolic Research

Pramlintide

Broader research index
BROADER RESEARCH INDEXEVIDENCE INDEX

Amylin-analogue research

EVIDENCE CONTEXTEstablished human clinical literature
OPEN EVIDENCE PROFILE →
PT-141
Endocrine Research

PT-141

10mg
ENHANCED CATALOGUESOURCE + EXPOSURE MAPPED

Melanocortin-receptor research

EVIDENCE CONTEXTProfile context
STUDIED EXPOSURE1.75 mgSubcutaneous · as-needed study administration
OPEN EXPOSURE MAP →RESEARCH PROFILE ↗
Retatrutide
Metabolic Research

Retatrutide

10mg · 20mg
ENHANCED CATALOGUESOURCE + EXPOSURE MAPPED

GLP-1, GIP and glucagon receptor research

EVIDENCE CONTEXTProfile context
STUDIED EXPOSURE1 mg · 4 mg · 8 mgSubcutaneous · once weekly
OPEN EXPOSURE MAP →RESEARCH PROFILE ↗
Selank
Cognitive & Neuro Support

Selank

10mg
ENHANCED CATALOGUEEVIDENCE INDEX

Neurobiology and stress-response research

EVIDENCE CONTEXTProfile context
RESEARCH PROFILE ↗
Semaglutide ENHANCED Research Index vial
Metabolic Research

Semaglutide

Broader research index
BROADER RESEARCH INDEXSOURCE + EXPOSURE MAPPED

GLP-1 receptor agonist research

EVIDENCE CONTEXTExtensive human clinical literature
STUDIED EXPOSURE2 mg · 8 mg · 16 mgSubcutaneous · once weekly
OPEN EXPOSURE MAP →
Semax
Cognitive & Neuro Support

Semax

10mg
ENHANCED CATALOGUESOURCE + EXPOSURE MAPPED

Neurobiology and cognitive-signalling research

EVIDENCE CONTEXTProfile context
STUDIED EXPOSURE1.2 mg totalIntranasal · 1% solution
OPEN EXPOSURE MAP →RESEARCH PROFILE ↗
Sermorelin ENHANCED Research Index vial
Growth Signalling

Sermorelin

Broader research index
BROADER RESEARCH INDEXEVIDENCE INDEX

GHRH(1–29) research

EVIDENCE CONTEXTHuman clinical / diagnostic literature
OPEN EVIDENCE PROFILE →
Setmelanotide ENHANCED Research Index vial
Endocrine Research

Setmelanotide

Broader research index
BROADER RESEARCH INDEXEVIDENCE INDEX

MC4 receptor agonist research

EVIDENCE CONTEXTEstablished human clinical literature
OPEN EVIDENCE PROFILE →
SHLP-2 ENHANCED Research Index vial
Longevity & Cellular

SHLP-2

Broader research index
BROADER RESEARCH INDEXEVIDENCE INDEX

Small humanin-like peptide research

EVIDENCE CONTEXTEarly translational
OPEN EVIDENCE PROFILE →
SS31
Longevity Research

SS31

50mg
ENHANCED CATALOGUESOURCE + EXPOSURE MAPPED

Mitochondrial-targeting peptide research

EVIDENCE CONTEXTProfile context
STUDIED EXPOSURE0.01 mg/kg/h · 0.1 mg/kg/h · 0.25 mg/kg/hIntravenous infusion
OPEN EXPOSURE MAP →RESEARCH PROFILE ↗
Survodutide ENHANCED Research Index vial
Metabolic Research

Survodutide

Broader research index
BROADER RESEARCH INDEXSOURCE + EXPOSURE MAPPED

GLP-1 + glucagon dual-agonist research

EVIDENCE CONTEXTHuman phase 2–3
STUDIED EXPOSURE2.4 mg · 4.8 mg · 6.0 mgSubcutaneous · once weekly
OPEN EXPOSURE MAP →
Tesamorelin
Performance & Recovery

Tesamorelin

10mg
ENHANCED CATALOGUESOURCE + EXPOSURE MAPPED

GHRH analogue and metabolic research

EVIDENCE CONTEXTProfile context
STUDIED EXPOSURE2 mgSubcutaneous · daily
OPEN EXPOSURE MAP →RESEARCH PROFILE ↗
Thymosin Alpha 1
Longevity Research

Thymosin Alpha 1

10mg
ENHANCED CATALOGUESOURCE + EXPOSURE MAPPED

Immune-signalling research

EVIDENCE CONTEXTProfile context
STUDIED EXPOSURE0.8–6.4 mg · 1.6–16 mgPrimarily subcutaneous in the reviewed clinical literature
OPEN EXPOSURE MAP →RESEARCH PROFILE ↗
Thymosin Beta-4 ENHANCED Research Index vial
Recovery & Tissue

Thymosin Beta-4

Broader research index
BROADER RESEARCH INDEXEVIDENCE INDEX

Actin-binding / tissue-repair research

EVIDENCE CONTEXTHuman topical + preclinical systemic
OPEN EVIDENCE PROFILE →
Tirzepatide ENHANCED Research Index vial
Metabolic Research

Tirzepatide

Broader research index
BROADER RESEARCH INDEXSOURCE + EXPOSURE MAPPED

GIP + GLP-1 receptor agonist research

EVIDENCE CONTEXTExtensive human clinical literature
STUDIED EXPOSURE5 mg · 10 mg · 15 mgSubcutaneous · once weekly
OPEN EXPOSURE MAP →
VIP ENHANCED Research Index vial
Neuro & Immune

VIP

Broader research index
BROADER RESEARCH INDEXEVIDENCE INDEX

Vasoactive-intestinal-peptide research

EVIDENCE CONTEXTHuman physiology + clinical exploration
OPEN EVIDENCE PROFILE →
Wolverine Blend
Performance & Recovery

Wolverine Blend

10mg · 20mg
ENHANCED CATALOGUEEVIDENCE INDEX

Higher-strength recovery blend research

EVIDENCE CONTEXTProfile context
RESEARCH PROFILE ↗
No matching research entries.
Important: “Studied exposure” means a dose, concentration or infusion rate reported by the linked source. It is not a suggested amount. Animal exposures are never converted to human equivalents, and different routes are never treated as interchangeable.